Home › Research › Risk genes beyond APOE
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals
Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P.. Experimental gerontology, 2002-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Active immunization with the human amyloid peptide (Abeta42) or passive immunization with anti-Abeta42 antibodies protects mice that express a mutant human amyloid precursor protein (APP) transgene from cerebral amyloid deposits. If anti-Abeta42 antibodies protect APP-transgenic mice, a model of Alzheimer's disease (AD), a high titer of anti-Abeta42 antibodies may protect humans from AD. The titer of anti-Abeta42 antibodies in serum from individuals with and without late onset AD was measured using an ELISA.
What this study adds
Evidence grade: Low
Because anti-amyloid antibodies protect mouse models from amyloid deposits, this study measured natural anti-Aβ42 antibodies in the blood of people with late-onset Alzheimer's and of healthy elderly controls. Controls had significantly higher levels, and IgG antibodies distinguished patients from controls among people without the APOE4 allele.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Weksler, M. E., Relkin, N., Turkenich, R., LaRusse, S., Zhou, L., & Szabo, P. (2002). Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Experimental gerontology. https://doi.org/10.1016/s0531-5565(02)00029-3
Vancouver
Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Experimental gerontology. 2002. doi:10.1016/s0531-5565(02)00029-3. PMID: 12086704.
BibTeX
@article{weksler2002-12086704,
author = {Weksler, M. E. and Relkin, N. and Turkenich, R. and LaRusse, S. and Zhou, L. and Szabo, P.},
title = {{Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals}},
journal = {Experimental gerontology},
year = {2002},
doi = {10.1016/s0531-5565(02)00029-3},
pmid = {12086704},
url = {https://doi.org/10.1016/s0531-5565(02)00029-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- If anti-Abeta42 antibodies protect APP-transgenic mice, a model of Alzheimer's disease (AD), a high titer of anti-Abeta42 antibodies may protect humans from AD.
- The titer of anti-Abeta42 antibodies in serum from individuals with and without late onset AD was measured using an ELISA.
- The titer of Ig (IgM, IgG and IgA) and IgG anti-Abeta42 peptide antibodies was significantly higher in serum from elderly controls than AD patients.
- Furthermore, IgG but not Ig anti-Abeta42 antibodies distinguished sera from AD patients and elderly controls that did not have the apolipoprotein E4 allele.
Why it matters
Because anti-amyloid antibodies protect mouse models from amyloid deposits, this study measured natural anti-Aβ42 antibodies in the blood of people with late-onset Alzheimer's and of healthy elderly controls. Controls had significantly higher levels, and IgG antibodies distinguished patients from controls among people without the APOE4 allele. This fits the authors' idea that a high level of these antibodies may protect against Alzheimer's, though it shows a link, not proof.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Experimental gerontology) |
| Journal's citation record | 2 / 4 | Experimental Gerontology: journal h-index 195 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 201 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.7 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 3 / 6 | Cited 3.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Paul Szabo: h-index 28 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Cornell University: institution h-index 1,649 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12086704) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Risk genes beyond APOE from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.